Citations

Clear

229 citation(s) found for "Chow, W".

Computed Tomography Evaluation of Coronary Atherosclerosis: The Road Travelled, and What Lies Ahead
Ayoub, Chadi , Scalia, Isabel G. , Anavekar, Nandan S., Arsanjani, Reza , Jokerst, Clinton, Kritharides, Leonard , Kritharides, Leonard , Arsanjani, Reza , Scalia, Isabel G , Chow, Benjamin J.W.

Mayo Clinic

Diagnostics | September 23, 2024 | Volume: 14 | Issue: 18 | Pages: 2096

10.3390/diagnostics14182096 | PMID 39335775 Get It

Coronary CT angiography (CCTA) is now endorsed by all major cardiology guidelines for the investigation of chest pain and assessment for coronary artery disease (CAD) in appropriately selected patients. CAD is a leading cause of morbidity and mortality. There is extensive literature to support CCTA diagnostic and prognostic value both for stable and acute symptoms. It enables rapid and cost-effective rule-out of CAD, and permits quantification and characterization of coronary plaque and associated significance. In this comprehensive review, we detail the road traveled as CCTA evolved to include quantitative assessment of plaque stenosis and extent, characterization of plaque characteristics including high-risk features, functional assessment including fractional flow reserve-CT (FFR-CT), and CT perfusion techniques. The state of current guideline recommendations and clinical applications are reviewed, as well as future directions in the rapidly advancing field of CT technology, including photon counting and applications of artificial intelligence (AI).
Randomised controlled trials on radiation dose fractionation in breast cancer: systematic review and meta-analysis with emphasis on side effects and cosmesis
Lee, Shing Fung , Kennedy, Samantha , Caini, Saverio, Wong, Henry C.Y., Poortmans, Philip , Meattini, Icro , Recht, Abram , Hijal, Tarek , Torres, Mylin A. , Cao, Jeffrey , Corbin, Kimberly S. , Choi, J. Isabelle , Koh, Wee Yao , Kwan, Jennifer , Karam, Irene , Chow, Edward , Wong, Henry C. Y. , Meattini, Icro , Hijal, Tarek , Kennedy, Samantha K. F. , Caini, Saverio , Yip, Pui Lam , Kaidar-Person, Orit , Chan, Adrian Wai , Marta, Gustavo Nader

Mayo Clinic

BMJ | September 11, 2024 | Volume: 386 | Issue: No issue available | Pages: e079089

10.1136/bmj-2023-079089 | PMID 39260879 Get It

Abstract Objective To provide a comprehensive assessment of various fractionation schemes in radiation therapy for breast cancer, with a focus on side effects, cosmesis, quality of life, risks of recurrence, and survival outcomes. Design Systematic review and meta-analysis. Data sources Ovid MEDLINE, Embase, and Cochrane Central Register of Controlled Trials (from inception to 23 October 2023). Study selection Included studies were randomised controlled trials focusing on conventional fractionation (CF; daily fractions of 1.8-2 Gy, reaching a total dose of 50-50.4 Gy over 5-6 weeks), moderate hypofractionation (MHF; fraction sizes of 2.65-3.3 Gy for 13-16 fractions over 3-5 weeks), and/or ultra-hypofractionation (UHF; schedule of only 5 fractions). Data extraction Two independent investigators screened studies and extracted data. Risk of bias and quality of evidence were assessed using the Cochrane Collaboration’s tool and the GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) approach, respectively. Data synthesis Pooled risk ratios (RRs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using a random effects model. Heterogeneity was analysed using Cochran’s Q test and I 2 statistic. Network meta-analysis was used to integrate all available evidence. Main outcome measures The pre-specified primary outcome was grade ≥2 acute radiation dermatitis and late radiation therapy related side effects; secondary outcomes included cosmesis, quality of life, recurrence, and survival metrics. Results From 1754 studies, 59 articles representing 35 trials (20 237 patients) were assessed; 21.6% of outcomes showed low risk of bias, whereas 78.4% had some concerns or high risk, particularly in outcome measurement (47.4%). The RR for grade ≥2 acute radiation dermatitis for MHF compared with CF was 0.54 (95% CI 0.49 to 0.61; P<0.001) and 0.68 (0.49 to 0.93; P=0.02) following breast conserving therapy and mastectomy, respectively. Hyperpigmentation and grade ≥2 breast shrinkage were less frequent after MHF than after CF, with RRs of 0.77 (0.62 to 0.95; P=0.02) and 0.92 (0.85 to 0.99; P=0.03), respectively, in the combined breast conserving therapy and mastectomy population. However, in the breast conserving therapy only trials, these differences in hyperpigmentation (RR 0.79, 0.60 to 1.03; P=0.08) and breast shrinkage (0.94, 0.83 to 1.07; P=0.35) were not statistically significant. The RR for grade ≥2 acute radiation dermatitis for UHF compared with MHF was 0.85 (0.47 to 1.55; P=0.60) for breast conserving therapy and mastectomy patients combined. MHF was associated with improved cosmesis and quality of life compared with CF, whereas data on UHF were less conclusive. Survival and recurrence outcomes were similar between UHF, MHF, and CF. Conclusions MHF shows improved safety profile, cosmesis, and quality of life compared with CF while maintaining equivalent oncological outcomes. Fewer randomised controlled trials have compared UHF with other fractionation schedules, but its safety and oncological effectiveness seem to be similar with short term follow-up. Given the advantages of reduced treatment time, enhanced convenience for patients, and potential cost effectiveness, MHF and UHF should be considered as preferred options over CF in appropriate clinical settings, with further research needed to solidify these findings. Systematic review registration PROSPERO CRD42023460249.
Feasibility of structuring electronic health record data to facilitate real‐world data research: ICAREdata methods applied to multicenter cancer clinical trials
Campbell, Nancy , Hillman, Shauna L., Harlos, Elizabeth S., Stein, David , Chan, Miranda Y., Chow, Selina , Elrahi, Cassandra , Quina, Andre , Kokolus, Maeve C., Casagni, Michelle , Weiss, Matthias , Anderson, Daniel M. , Hoff, Olivia C., Rivera, Donna R. , Mandrekar, Sumithra J. , Piantadosi, Steven , Stadler, Walter M , Piantadosi, Steven , George, Suzanne , Campbell, Nancy, Stadler, Walter M. , Kluetz, Paul Gustav

Mayo Clinic

Cancer | August 28, 2024 | Volume: 131 | Issue: 1 | Pages: No page available

10.1002/cncr.35528 | PMID 39192753 Get It

AbstractBackgroundThe use of electronic health record (EHR) data for research is limited by a lack of structure and a standard data model. The objective of the ICAREdata (Integrating Clinical Trials and Real‐World Endpoints Data) project was to structure key research data elements in EHRs using a minimal Common Oncology Data Elements (mCODE) data model to extract and transmit data.MethodsThe ICAREdata project captured two EHR data elements essential to clinical trials: cancer disease status and treatment plan change. The project was implemented in clinical sites participating in Alliance for Clinical Trials in Oncology trials. Data were extracted from EHRs and sent by secure Fast Healthcare Interoperability Resource messaging (a standard for exchanging EHRs) to a database. Selected elements were compared with corresponding data from the trial's electronic data capture (EDC) system, Medidata Rave.ResultsBy December 2023, data were extracted and transmitted from 10 sites for 35 patients, involving 367 clinical encounters across 15 clinical trials. Data through March 2023 demonstrated that concordance for the elements treatment plan change and cancer disease status was 79% and 34%, respectively. When disease evaluation was reported by both EHR and EDC (n = 15), there was 87% agreement on cancer disease status.ConclusionsDocumentation, extraction, and aggregation of structured data elements in EHRs using mCODE and ICAREdata methods is feasible in multi‐institutional cancer clinical trials. EDC as a reference data set allowed assessment of the completeness of EHR data capture. Future initiatives will focus on elements with shared definitions in clinical and research environments and efficient workflows.Plain Language Summary Clinical trials use electronic case report forms to report data, and data must be manually entered on these forms, which is costly and time consuming. ICAREdata methods use structured, organized data from clinical trials that can be more easily shared instead having to enter free text into electronic health records.
Improving Surgical Care and Outcomes in Older Cancer Patients Through Implementation of a Presurgical Toolkit (OPTI-Surg)—Final Results of a Phase III Cluster Randomized Trial (Alliance A231601CD)
Chang, George J. , Gunn, Heather, Barber, Anne K., Lowenstein, Lisa M. , Dohan, Daniel , Dockter, Travis , Tan, Angelina D., Dueck, Amylou C. , Chow, Selina , Neuman, Heather B. , Finlayson, Emily , Investigators, on behalf of the OPTI-Surg, Dueck, A. C. , Gunn, Heather J., Barber, Anne, Broering, Jeanette M. , Investigators, on behalf of the OPTI-Surg

Mayo Clinic

Annals of Surgery | July 29, 2024 | Volume: 280 | Issue: 4 | Pages: 623-632

10.1097/sla.0000000000006458 | PMID 39069901 Get It

Objective: To assess the effect of a practice-level preoperative frailty screening and optimization toolkit (OPTI-Surg) on postoperative functional recovery and complications in elderly cancer patients undergoing major surgery. Background: Frailty is common in older adults. It increases the risk of poor postoperative functional recovery and complications. The potential for a practice-level screening/optimization intervention to improve outcomes is unknown. Methods: Thoracic, gastrointestinal, and urologic oncological surgery practices within the National Cancer Institute Community Oncology Research Program (NCORP) were randomized 1:1:1 to usual care (UC), OPTI-Surg, or OPTI-Surg with an implementation coach. OPTI-Surg consisted of the Edmonton Frail Scale and guided recommendations for referral interventions. Patients 70 years old or above undergoing curative intent surgery were eligible. The primary outcome was 8 weeks postoperative function (kcal/wk). The key secondary outcome was complications within 90 days. Mixed models were used to compare UC to the 2 OPTI-Surg arms combined. Results: From July 2019 to September 2022, 325 patients were enrolled in 29 practices. One hundred ninety-nine (64 UC, 135 OPTI-Surg) and 279 (78 UC, 201 OPTI-Surg) were evaluable for primary and secondary analysis, respectively. UC and OPTI-Surg patients did not significantly differ in total caloric expenditure (2.2 UC, 2.0 OPTI-Surg) after adjusting for baseline function (P=0.53). UC and OPTI-Surg patients did not significantly differ in postoperative complications (25.6% UC, 35.3% OPTI-Surg, P=0.5). Conclusions: Frailty assessment was successfully performed, but the OPTI-Surg intervention did not improve postoperative function nor reduce postoperative complications compared with UC. Future analysis will explore practice-level factors associated with toolkit implementation and the differences between the coaching and noncoaching arms.
Survival loss linked to guideline-based indications for degenerative mitral regurgitation surgery
Vancraeynest, David , Gerber, Bernhard, Benfari, Giovanni , Essayagh, Benjamin , Tribouilloy, Christophe , Ruşinaru, Dan, Ewe, See Hooi , investigators, MIDA (Mitral Regurgitation International Database), Antoine, Clémence , Malouf, Joseph F., Michelena, Hector, Guerra, Federico, Russo, Antonio Dello, Chow, Josie , Fan, Yiting , Keh, Yann Shan , Hamid, Nadira , Pin, Ding Zee, Trojette, Faouzi, Touati, Gilles, Rémadi, Jean Paul , Poulain, H, Ditaranto, Raffaello , Caponetti, Giuseppe, Savini, Carlo , Melfi, Rosetta, Meester, Christophe de, Khoury, Gébrine El , Gerber, Bernhard , Pasquet, Agnès, Collart, Frédéric , Avierinos, Jean Francois, Rossi, Andrea , Essayagh, Benjamin , Tribouilloy, Christophe , Bursi, Francesca , Biagini, Elena , Enriquez-Sarano, Maurice , Benfari, Giovanni , Pouleur, Anne–Catherine , Meester, Christophe de , Pasquet, Agnès , Michelena, Héctor I. , Grigioni, Francesco , Barbieri, Andréa , Bursi, Francesca , Aviérinos, Jean-François , Guerra, Federico , Yeo, Khung Keong , Lee, Alex Pui‐Wai , Vanoverschelde, Jean‐Louis , Enriquez‐Sarano, Maurice , investigators, MIDA (Mitral Regurgitation International Database), Michelena, Hector, Nkomo, Vuyisile T. , Guerra, Federico, Barbarossa, Alessandro , Russo, Antonio Dello, Wong, Randolph H.L. , Wan, Song , Caponetti, Giuseppe Angelo, Pacini, Davide , Chello, Massimo , Nusca, Annunziata , Ussia, Gian Paolo , Meester, Christophe de, Pasquet, Agnès, Théron, Alexis , Avierinos, Jean-Fançois, Mantovani, Francesca , Modena, Maria Grazia , Boriani, Giuseppe , Onorati, Francesco , Ribichini, Flavio Luciano

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | July 11, 2024 | Volume: 25 | Issue: 12 | Pages: 1703-1711

10.1093/ehjci/jeae176 | PMID 38996050 Get It

Abstract Aims Operating on patients with severe degenerative mitral regurgitation (DMR) is based on ACC/AHA or ESC/EACTS guidelines. Doubts persist on best surgical indications and their potential association with postoperative survival loss. We sought to investigate whether guideline-based indications lead to late postoperative survival loss in DMR patients. Methods and results We analysed outcome of 2833 patients from the Mitral Regurgitation International Database registry undergoing surgical correction of DMR. Patients were stratified by surgical indications: Class I trigger (symptoms, left ventricular end-systolic diameter ≥ 40 mm, or left ventricular ejection fraction &lt; 60%, n = 1677), isolated Class IIa trigger [atrial fibrillation (AF), pulmonary hypertension (PH), or left atrial diameter ≥ 55 mm, n = 568], or no trigger (n = 588). Postoperative survival was compared after matching for clinical differences. Restricted mean survival time (RMST) was analysed. During a median 8.5-year follow-up, 603 deaths occurred. Long-term postoperative survival was lower with Class I trigger than in Class IIa trigger and no trigger (71.4 ± 1.9, 84.3 ± 2.3, and 88.9 ± 1.9% at 10 years, P &lt; 0.001). Having at least one Class I criterion led to excess mortality (P &lt; 0.001), while several Class I criteria conferred additional death risk [hazard ratio (HR): 1.53, 95% confidence interval (CI): 1.42–1.66]. Isolated Class IIa triggers conferred an excess mortality risk vs. those without (HR: 1.46, 95% CI: 1.00–2.13, P = 0.05). Among these patients, isolated PH led to decreased postoperative survival vs. those without (83.7 ± 2.8% vs. 89.3 ± 1.6%, P = 0.011), with the same pattern observed for AF (81.8 ± 5.0% vs. 88.3 ± 1.5%, P = 0.023). According to RMST analysis, compare to those operated on without triggers, operating on Class I trigger patients led to 9.4-month survival loss (P &lt; 0.001) and operating on isolated Class IIa trigger patients displayed 4.9-month survival loss (P = 0.001) after 10 years. Conclusion Waiting for the onset of Class I or isolated Class IIa triggers before operating on DMR patients is associated with postoperative survival loss. These data encourage an early surgical strategy.
Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU)
Solomon, Scott R. , Arnason, Jon , Johnston, Patrick B. , Glaß, Bertram , Mutsaers, Pim , Hernandez‐Ilizaliturri, Francisco J. , Lunning, Matthew A. , Chow, Victor A. , Santamaria, Josu, Colicino, Silvia , Stepan, Lara , Kamdar, Manali , Bachanová, Veronika , Ibrahimi, Sami , Mielke, Stephan , Izutsu, Koji , Morschhauser, Franck , Ogasawara, Ken , Abramson, Jeremy S.

Mayo Clinic

Journal of Clinical Oncology | June 28, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 7013-7013

10.1200/jco.2024.42.16_suppl.7013 Get It

7013 Background: Liso-cel is an autologous, CD19-directed, 4-1BB CAR T cell product. In prespecified interim and primary analyses of TRANSFORM (NCT03575351), liso-cel showed significant improvements in efficacy vs SOC in pts with R/R LBCL. Here we report results after ~3-y FU. Methods: TRANSFORM is a randomized phase 3 study comparing liso-cel vs SOC (CT [R-DHAP, R-ICE, or R-GDP] then high-dose CT [HDCT] + ASCT) in adults aged ≤ 75 y with LBCL primary refractory to or relapsed ≤ 12 mo after first-line therapy and eligible for ASCT. Liso-cel arm pts underwent lymphodepletion followed by liso-cel (100 × 10 6 CAR + T cells). Bridging therapy was allowed. SOC arm pts received 3 cycles of CT; responding pts proceeded to HDCT + ASCT. Crossover to receive liso-cel was allowed for SOC arm pts if criteria were met. The primary endpoint was event-free survival (EFS) per independent review committee (IRC). Key secondary endpoints included CR rate and PFS per IRC, and OS. Endpoints were not statistically retested and are reported descriptively. Results: In total, 184 pts were randomized (92 per arm); baseline characteristics were reported (Abramson et al. Blood 2023). Median (range) FU was 33.9 mo (0.9–53.0). Median EFS, PFS, and duration of response (DOR) were longer for liso-cel vs SOC, similar to the primary analysis (Table). A total of 61 (66%) SOC arm pts crossed over to receive liso-cel. Median OS was not reached (NR) in either arm; 36-mo OS rates were numerically higher for liso-cel. Of 76 total deaths (liso-cel, n = 34; SOC, n = 42 [crossover pts, n = 33]), 10 occurred since the primary analysis (liso-cel, n = 6; SOC, n = 4 [all crossover pts]); most were due to disease progression or complications (n = 6). Safety results were consistent with the primary analysis. Cellular kinetics and B-cell aplasia will be presented. Conclusions: After median FU of 33.9 mo, liso-cel as 2L treatment in pts with primary refractory or early relapsed LBCL resulted in deepening of response and continued improvement in efficacy endpoints over SOC, confirming the ongoing benefit of liso-cel. Clinical trial information: NCT03575351 . [Table: see text]
Characterizing outcomes of biliary tract cancers (BTC) with β-catenin (CTNNB1) alterations.
Chow, Lydia D., Hanna, Diana L. , Ganguly, Rituparna, Pai, Jonathan , Misirian, Ani , Algaze, Sandra , Akce, Mehmet , Iqbal, Syma , Shroff, Rachna T. , Lenz, Heinz‐Josef , Baca, Yasmine , Philip, Philip A. , Bekaii‐Saab, Tanios , El-Khoueiry, Anthony B.

Mayo Clinic

Journal of Clinical Oncology | June 21, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 4107-4107

10.1200/jco.2024.42.16_suppl.4107 Get It

4107 Background: Aberrant Wnt/β-catenin activation has been implicated in tumor formation and progression in BTC. CTNNB1 is a key transcriptional co-activator in Wnt signaling. The impact of CTNNB1 alterations on outcomes in intrahepatic (IHCC) vs extrahepatic (EHCC) vs gallbladder (GB) tumors and patterns of gene co-expression is unclear. We examined the molecular correlates and predictive and prognostic significance of CTNNB1 expression in a real-world cohort of pts with BTC. Methods: 7450 BTC tumors were analyzed using Next Generation Sequencing (NextSeq), Whole Exome and Whole Transcriptome Sequencing (NovaSeq) at Caris Life Sciences (Phoenix, AZ). Top quartile transcripts per million (TPM) expression was considered high expressors (Q4), bottom quartile was considered low expressors (Q1) within each subtype. Real-world overall survival (OS) data was obtained from insurance claims. Hazard ratio (HR) was calculated using Cox proportional hazards model, P values were calculated using log-rank test. Significance was determined to be p <0.05. Chi-square and Mann-Whitney tests determined molecular differences between subgroups and adjusted for multiple comparisons (q<0.05). Results: The cohort was comprised of 61% IHCC, 14% EHCC, 23% GB, 2% NOS. CTNNB1 mutations are rare in BTC (1.3%). Pts with CTNNB1-wt tumors had significantly better OS vs CTNNB1-mt (13.6 vs 10.2 mo, HR 0.74, p=0.008). This association remained significant in IHCC (13.2 vs 4.5 mo, HR 0.64, p=0.031) but not EHCC (18.0 vs 11.8 mo, HR 0.87, p=0.64) or GB (12.9 vs 11.0 mo, HR 0.75, p=0.071). CTNNB1-mt tumors were more frequently TP53-mt (63% vs 41%), ERBB2-mt (9% vs 2%) and ATM-mt (9% vs 3%). CTNNB1-wt tumors were more likely BAP-mt (9% vs 0%) and IDH1-mt (10% vs 0%) (all q<0.05). CTNNB1-mt tumors had higher median CTNNB1 expression vs wt (154.9 vs 113.4, q<0.009). Pts with CTNNB1 Q1 expression had significantly better OS vs Q4 (14.5 vs 12.4 mo, HR 0.88, p=0.007). This association held in IHCC (15.0 vs 10.6 mo, HR 0.77, p<0.00001) but not EHCC (17.5 vs 19.9 mo, HR 1.05, p=0.70) or GB (12.4 vs 12.8 mo, HR 1.05, p=0.63). CTNNB1 Q4 expressing tumors were more likely to be TP53-mt (55% vs 34%), PIK3CA-mt (9% vs 5%), KRAS-mt (23% vs 12%) and less likely IDH1-mt (4% vs 14%) compared to Q1 (all q<0.05). CTNNB1 Q4 pts had higher ARID1A, CTLA4, LAG3, HIF1A, TGFB1/2/3, EPHB4, EPHA2, VEGFA expression (FC: 2.1-4.2, all q<0.05) and higher T-cell inflamed score vs Q1. There was a trend towards improved OS in pts with IHCC CTNNB1 Q1 tumors receiving gemcitabine or fluorouracil (17.5 vs 15.0 mo, HR 0.86, p=0.064); no difference in outcomes by CTNNB1 expression in pts receiving immunotherapy. Conclusions: CTNNB1 mutations and mRNA expression levels impact survival in BTC, especially IHCC, and may be associated with benefit from chemotherapy. CTNBB1 alterations are associated with immunogenic, DNA repair and angiogenic pathways and may help identify novel therapeutic strategies for BTC.
Impact of CTNNB1 alterations on outcomes in patients with hepatocellular carcinoma (HCC).
Pai, Jonathan , Ganguly, Rituparna, Akce, Mehmet , Algaze, Sandra , Chow, Lydia D., Misirian, Ani, Hanna, Diana L. , Lenz, Heinz‐Josef , Iqbal, Syma , Shroff, Rachna T. , Baca, Yasmine , Misirian, Ani , Marshall, John K. , Borad, Mitesh J. , El-Khoueiry, Anthony B.

Mayo Clinic

Journal of Clinical Oncology | June 21, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 4106-4106

10.1200/jco.2024.42.16_suppl.4106 Get It

4106 Background: The WNT/beta catenin (CTNNB1) pathway plays an integral role in the development of HCC. CTNNB1 has been implicated in HCC progression, metastasis, and drug resistance. We examined associations between CTNNB1 mutations and mRNA expression and clinical outcomes in a real-world cohort of patients with HCC. Methods: 1652 HCC tumors were tested at Caris Life Sciences (Phoenix, AZ) and analyzed with Whole Transcriptome Sequencing (WTS; Illumina Novaseq), Whole Exome Sequencing (NovaSeq,WES) and NextGen DNA sequencing (NextSeq, 592 genes). mRNA expression (transcripts per million) was further stratified into top (Q4) and bottom quartiles (Q1). Kaplan Meier estimates were calculated for overall survival (OS) in the molecularly defined cohorts and estimated from time of tissue collection to last contact. Significance was determined to be p <0.05. Chi-square and Mann-Whitney tests determined molecular differences between subgroups and adjusted for multiple comparisons (q<0.05). Results: Pathogenic CTNNB1 mutations were present in 32% of HCC and mutation status was not associated with CTNNB1 expression level. Pts whose tumors had lower CTNNB1 expression had significantly improved OS, 17.9 vs 12.4 months, Q1 vs Q4, HR 0.72, CI: 0.58-0.89 p=0.002. This association remained significant in patients who received first-line IO (Q1 vs Q4: OS 16.7 vs 10.6 mo, HR 0.54, CI: 0.32-0.94, p=0.025) or TKI (Q1 vs Q4: OS 27.1 vs 17.6 mo, HR 0.60, CI: 0.38-0.94, p=0.025). Low CTNNB1-expressing tumors (Q1) had more frequent ARID1A mutations (15% vs 8%); less frequent TP53 mutations (31% vs 42%); lower VEGFA, EPHB4, EPHA2, HIF1A, TGFB1/2/3 expression, lower MAPK activation and lower T-cell inflamed scores vs Q4 tumors (all q < 0.05). All tumors were MSS. CTNNB1 mutation status (MT vs WT) did not impact survival (OS 17.6 vs 15.3 mo, CTNNB1-MT vs CTNNB1-WT, HR 1.05, CI: 0.91-1.20, p=0.55). Similarly, CTNNB1 mutation status (MT vs WT) did not impact OS in pts treated with IO (19.8 vs 19.6 mo, HR 0.99, p=0.94) or TKI (23.0 vs 22.0 mo, HR 0.86, p=0.33). Conclusions: CTNNB1 mRNA expression, but not CTNNB1 mutation status, is associated with survival in HCC. Patients whose tumors had lower CTNNB1 expression appeared to derive more benefit from immune checkpoint inhibitors and TKI therapy in first line. CTNNB1 expression is associated with DNA repair, immune, neuronal and angiogenic pathways which may pave the way for potential therapeutic opportunities. Further studies are needed to prospectively evaluate CTNNB1 as a biomarker for treatment selection in HCC.
Alliance A222001: A randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy.
Stish, B.J., Mazza, Gina L. , Nauseef, Jones T. , Humeniuk, Michael, Tofthagen, Cindy , Pardo, D.A. Diaz, Chay, Christopher H., Huang, Andrew Jonathan, Naha, Kushal , Chow, Selina , Adams‐Campbell, Lucile L. , Novotny, Paul J. , Loprinzi, Charles L. , Tofthagen, Cindy S , Mazza, Gina L , Smith, Thomas J. , Tagawa, Scott T.

Mayo Clinic

Journal of Clinical Oncology | June 5, 2024 | Volume: 42 | Issue: 17_suppl | Pages: LBA12004-LBA12004

10.1200/jco.2024.42.17_suppl.lba12004 Get It

LBA12004 Background: Hot flashes are among the most common adverse events impacting quality of life reported by patients receiving androgen deprivation therapy (ADT) for the treatment of prostate cancer. Oxybutynin is an effective therapy for reducing frequency and severity of hot flashes in women. Pilot information supports that this drug may also benefit men with hot flashes related to ADT. Methods: Patients with prostate cancer receiving a stable regimen of ADT with at least 28 hot flashes per week were randomized to receive either oral oxybutynin 2.5 mg twice a day, oxybutynin 5 mg twice a day, or matching placebo doses for 6 weeks. The primary endpoint was the change in patient-reported hot flash scores (determined by multiplying the number of hot flashes by the mean hot flash severity [grade 0: none, 1: mild, 2: moderate, 3: severe, and 4: very severe]) from baseline to 6 weeks, as measured by a daily hot flash diary. A total of 87 patients provided 76% power to reject the null hypothesis of no between-arm mean difference in hot flash score reduction from baseline to 6 weeks, when comparing each oxybutynin arm to the combined placebo arms. This was based on a two-sided contrast estimated from a generalized linear mixed model, α= 0.10, intraclass correlation of 0.50, population standardized mean difference of 0.50, and 10% missing data rate. Results: 88 patients were accrued between 10/28/21 and 12/02/23. Six patients cancelled before starting treatment and one was ineligible, leaving 81 analyzed patients with a median age of 68. Baseline characteristics were balanced between arms with patients reporting an average of 10.15 (SD = 5.55) hot flashes per day and an average daily hot flash score of 18.23 (SD = 13.48) at enrollment. On average, patients on the placebo arm, low dose oxybutynin arm, and high dose oxybutynin arm had reductions of 2.15, 4.77, and 6.89 hot flashes/day, respectively. Compared to placebo arm patients, high dose oxybutynin arm patients had a greater reduction in hot flashes/day (p < 0.001), as did low dose oxybutynin arm patients (p = 0.02). Daily hot flash scores for the same three protocol arms reduced by an average of 4.85, 9.94, and 13.95 points, respectively. Compared to placebo arm patients, high dose oxybutynin arm patients had a greater reduction in daily hot flash scores (p = 0.002), as did low dose oxybutynin arm patients (p = 0.07). No treatment-related grade 3+ adverse events occurred. The most commonly reported oxybutynin-related grade 2 adverse event was dry mouth. Conclusions: Oxybutynin is superior to a placebo for the management of hot flashes in men associated with androgen deprivation therapy and appears to be well tolerated. Support: UG1CA189823; https://acknowledgments.alliancefound.org . Clinical trial information: NCT04600336 .
High-Volume, High-Acuity, and High-Impact Learning: Tips and Tricks for Infectious Diseases Training Programs
Luther, Vera , Schultz, Sara , Aziz, Mariam, Balba, Gayle , McCarty, Todd P , Reece, Rebecca , Shnekendorf, Rachel, Sundareshan, Vidya, Chirch, Lisa M , Abdoler, Emily , Acharya, Kartikey, Bartash, Rachel , Blyth, Dana M , Casańas, Beata, Chow, Brian , Clough, Lisa , Cutrell, James B , Doshi, Saumil, Sanctis, Jorgelina de, Faulhaber, Jason, Fiske, Christina T. , Graber, Christopher J. , Johnson, Leonard B., Kwon, Taesung, Lastinger, Allison , Lee, Mi-Kyung , Leuck, Anne‐Marie , Lichtenberger, Paola , Gil, Raul Macias , Mattar, Caline , Matt, Brionna, Maziarz, Eileen K , Melia, Michael T. , Lora, Alfredo J Mena , Miko, Benjamin A. , Mitra, Subhashis , Nematollahi, Saman , Osorio, Georgina, Perez, Frederico , Phadke, Varun K. , Prakash, Katya , Reid, Gail, Riedel, David J. , Rojas‐Moreno, Christian , Salas, Natalie Mariam , Schlaffer, Kathryn, Sobhanie, Mohammad Mahdee , Solomon, Daniel A. , Vikram, Holenarasipur R. , Weber, Devin , Wooten, Darcy , Zerbe, Christa S. , McCarty, T P , Luther, Vera P , Vikram, Holenarasipur R. , Paras, Molly L , Razonable, Raymund R. , Azar, Marwan M. , Blumberg, Emily A. , Butt, Saira , Dare, Ryan K , Dobrzynski, David , Hazra, Aniruddha , Kaltsas, Anna , Kulkarni, Prathit A. , Marcos, Luis A. , Okeke, Nwora Lance , Stapleton, Ann E. , Streit, Judy A. , Thompson, George R , Schooneveld, Trevor Van , Velagapudi, Manasa , Weisenberg, Scott A.

Mayo Clinic

Open Forum Infectious Diseases | January 8, 2024 | Volume: 11 | Issue: 3 | Pages: No page available

10.1093/ofid/ofae016 | PMID 38434609 Get It

Abstract The Infectious Diseases Society of America Training Program Directors Committee met in October 2022 and discussed an observed increase in clinical volume and acuity on infectious diseases (ID) services, and its impact on fellow education. Committee members sought to develop specific goals and strategies related to improving training program culture, preserving quality education on inpatient consult services and in the clinic, and negotiating change at the annual IDWeek Training Program Director meeting. This paper outlines a presentation of ideas brought forth at the meeting and is meant to serve as a reference document for infectious diseases training program directors seeking guidance in this area.